Mean ± SD levels for the control, the DF, and the metastatic groups were 152.48 ± 49.76, 119.93 ± 60.66, and 96.32 ± 56.64 ng/mL, respectively (
P < 0.001,
R 2 = 12%,
Fig. 1). IGF-1 serum levels were statistically significantly higher in the control subjects than in both the DF patients (Dunnett
P = 0.012) and metastatic UM patients (Dunnett
P < 0.001). IGF-1 serum levels were not significantly higher in DF patients than in those who developed metastases (Tukey-Kramer honestly significant difference [HSD]
P = 0.224). Since IGF-1 levels decrease with age and our youngest metastatic patient was 57 years old, we repeated this analysis only for subjects over 50 years of age. Mean ± SD levels for the control, DF, and metastatic groups were 133.80 ± 27.25, 111.83 ± 45.80, and 96.32 ± 56.64 ng/mL, respectively (
P = 0.235,
R 2 = 4%).